Neurocrine Biosciences Inc. 13F holders
Of the 44 funds followed here, 9 reported a position in Neurocrine Biosciences Inc. in a 13F for the quarter ended 30 June 2026. The largest: Dodge & Cox, 5.6 million shares worth $941.2 million, 0.5% of its reported book.
| Fund | Shares | Value | Of its book | Change on the quarter | Status | Quarter ended | Filing |
|---|---|---|---|---|---|---|---|
| Dodge & Cox | 5,584,707 | $941.2 million | 0.5% | +123,670 | added | 30 June 2026 | 13F |
| Renaissance Technologies | 2,335,897 | $393.7 million | 0.5% | -83,000 | trimmed | 30 June 2026 | 13F |
| Geode Capital Management | 2,138,777 | $359.6 million | 0.0% | +2,105 | held | 30 June 2026 | 13F |
| Two Sigma Investments | 2,076,260 | $349.9 million | 0.3% | -984,310 | trimmed | 30 June 2026 | 13F |
| Norges Bank | 973,880 | $164.1 million | 0.0% | held | 30 June 2026 | 13F | |
| FMR LLC | 314,022 | $52.9 million | 0.0% | +159,155 | added | 30 June 2026 | 13F |
| Bridgewater Associates | 205,677 | $34.7 million | 0.1% | +57,536 | added | 30 June 2026 | 13F |
| Citadel Advisors | 72,563 | $12.2 million | 0.0% | -15,605 | trimmed | 30 June 2026 | 13F |
| Millennium Management | 11,585 | $2.0 million | 0.0% | -1,235,862 | trimmed | 30 June 2026 | 13F |
Value is what the fund reported.
Read more
Change is shares against the fund's previous 13F; a fund with one filing read shows no change. 13Fs cover long US positions of managers above $100 million and are filed up to 45 days after the quarter.Schedule 13D and 13G filed on the name, last twelve months
| Filed | Schedule | Who | Holding | Of the class | Event date | Rule or purpose | Filing |
|---|---|---|---|---|---|---|---|
| 27 July 2026 | 13G/A | Jpmorgan Chase & Co. and 1 other | 6.3 million | 6.3% | 30 June 2026 | passive, institutional (13d-1(b)) | EDGAR |
| 30 April 2026 | 13G | Vanguard Capital Management and 1 other | 5.3 million | 5.2% | 31 March 2026 | passive, institutional (13d-1(b)) | EDGAR |
| 27 March 2026 | 13G/A | The Vanguard Group and 1 other | 0 | 0.0% | 13 March 2026 | passive, institutional (13d-1(b)) | EDGAR |
| 21 January 2026 | 13G | Jpmorgan Chase & Co. and 1 other | 5.2 million | 5.2% | 31 December 2025 | passive, institutional (13d-1(b)) | EDGAR |
A Schedule 13D is filed by anyone who crosses 5% of a class with intent to influence; a 13G by a passive holder.
Read more
Amendments (/A) report a change, including an exit to zero. Holding and percentage are as the filer stated them on the cover page; the purpose is the filer's own words, cut short.Fails to deliver
| Settlement date | Shares failed | Price | File |
|---|---|---|---|
| 11 September 2026 | 1,221 | $156.57 | SEC |
| 9 September 2026 | 11 | $155.13 | SEC |
| 8 September 2026 | 19 | $155.64 | SEC |
| 28 August 2026 | 1,609 | $155.92 | SEC |
| 12 August 2026 | 20 | $161.94 | SEC |
| 7 August 2026 | 1 | $159.82 | SEC |
| 3 August 2026 | 5,960 | $166.80 | SEC |
Shares that failed to deliver at settlement, per day, from the SEC's half-month files, which arrive about two weeks after the period.
Read more
Largest in the window: 5,960 on 3 August 2026. A fail is an operational fact about settlement, not a position.Source
Each fund's 13F-HR on EDGAR, linked per row; positions matched to NBIX by CUSIP from the SEC's own fails-to-deliver files; Schedule 13D and 13G from the company's own filing index, each read to confirm the company is the issuer named.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.